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Drug discovery and the BBBDelivery of large molecule drugs across the blood brain
barrier is increasingly being seen as an achievable goal.
Several technologies have been described where fol-
lowing peripheral administration the molecules can be
detected in the brain. Foremost amongst these tech-
nologies are antibodies against the transferrin recep-
tor. Following a burst of publications in the very early
twenty first century, excitement seemed to wane as
contrary data started to emerge. Over the last few
years antibodies against transferrin receptor have
again started to raise hopes of successful drug delivery
to the central nervous system, as protein engineering
techniques have allowed a more detailed understand-
ing of the antibody properties necessary for successful
transport across the blood brain barrier.
Introduction
The development of antibody-based therapeutics has taken
huge steps forward in recent decades in all but a few fields.
The brain has remained inaccessible to immunotherapies as a
result of the barrier that separates it from the systemic circu-
lation; the blood:brain barrier (BBB). Specialised tight junc-
tions between the endothelial cells that make up the front
line of the BBB mean that whilst a small amount of most
antibodies will gain access to the brain after peripheral injec-*Corresponding author: C.I. Webster (websterc@medimmune.com)
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tion, this is reported to be as low as 0.1% of injected dose [1].
Therefore most antibodies would have to be administered at
very high levels in order to produce a therapeutic response,
which could lead to potentially toxic side effects. In this
review we will focus on one receptor that has been targeted,
the transferrin receptor, and discuss the challenges faced in
transporting large molecule therapeutics across the BBB.
Transferrin receptor as a route into the brain
Iron is an important molecule for brain function but must be
imported across the BBB for use by the cells of the brain, and
transferrin is the primary iron transporting protein [2]. Iron-
loaded transferrin (holo-transferrin) binds to transferrin
receptors on the surface of microvascular endothelial cells
and is transported across the BBB to the brain [3]. There is
some uncertainty as to whether iron is dissociated from
transferrin within the low pH endosomal compartments of
the brain endothelial cells before release on the abluminal
face or whether the holo-transferrin complex dissociates from
the transferrin receptor within endosomes, however it is clear
that the transferrin receptor must transcytose from the blood
to the brain side of the barrier to release its cargo. Technolo-
gies exploiting this transport pathway have been developed
that have the potential to deliver much needed treatments to
the central nervous system.ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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methods of delivering therapeutics to the brain are required.
A main focal point for brain targeting technology develop-
ment over the last couple of decades has been the so-called
‘Trojan horse’ method [4]. In this method an antibody is
developed that binds to an endogenous receptor on the
luminal face of the BBB endothelial cells. As the receptor is
internalised and transported through the cells, the antibody
is transported alongside and then released on the abluminal
side. Once the antibody has been established as a BBB-cross-
ing technology, it can be used to shuttle therapeutic mole-
cules into the brain to treat otherwise unreachable
conditions, for example, brain tumours, Alzheimer’s disease
and Parkinson’s disease.
Antibodies against transferrin receptor: unfulfilled
promise
The ability of transferrin receptor to bind and promote the
cellular uptake of a large protein lends itself to exploitation
for the development of an engineered solution for the deliv-
ery of recombinant proteins, such as antibodies, across the
BBB. Two antibodies in particular have been the subject of
extensive study: OX26 is a mouse monoclonal antibody
which recognises rat transferrin receptor [5] and 8D3 is a
rat antibody raised against the mouse transferrin receptor [6].
Both antibodies have been shown to bind to transferrin
receptor and internalise into brain endothelial cells without
interfering with the uptake of iron-bound transferrin. Jeff-
eries et al. [5] characterised the OX26 antibody as binding to
branched capillary structures in cryosections of the rat brain,
but not to the vasculature of other organs. They also showed
that intravenous injection of the OX26 antibody resulted in a
staining pattern that was indistinguishable from that of a
Factor VIII antibody, an established capillary marker. In
addition, a publication from Friden et al. [7] showed that
injection of OX26 resulted in detection of the antibody in the
brain vasculature of rats after one hour. A maximum value of
0.44% of the injected dose of OX26 was detectable in the
capillary-depleted fraction of the brain after 24 hours, sug-
gesting that the antibody was able to cross the BBB and access
the parenchyma. A subsequent publication by Pardridge et al.
[8] demonstrated that OX26 was able to bind to isolated
capillaries from bovine, human and rat brain, suggesting that
it bound a conserved transferrin receptor epitope. In addi-
tion, they repeated the capillary depletion experiments and
showed again that OX26 was detectable in the fraction
representing the brain parenchyma.
A study into the transport of OX26 across the BBB in rats
showed that the kinetics of OX26 were very different from
those of a non-immune isotype control antibody, with OX26
being cleared from plasma much more quickly [9]. However,
the authors observed that OX26 accumulated within the
brain at a much higher level than the control IgG following50 www.drugdiscoverytoday.comi.v. injection. Subsequent experiments using a capillary-de-
pletion technique demonstrated that, in contrast with previ-
ous studies, 90–95% of the amount of detectable OX26 was
associated with the capillary-containing pellet. This was con-
firmed with immunohistochemistry data showing that OX26
was mainly associated with brain capillaries throughout the
parenchyma. Interestingly, they also saw that OX26 was
associated with neurons only in areas that were in close
proximity to the ventricular system, suggesting that OX26
may have been accessing the brain via the blood-CSF barrier
or cerebroventricular organs. Detection of OX26 in the CSF
appeared to support this theory. The authors discussed the
problems of a high-affinity antibody-antigen interaction that
would be difficult to reverse in order for OX26 to be released
from the abluminal surface of brain endothelial cells follow-
ing transcytosis via the transferrin receptor, evidence for
which would come over a decade later.
An initial study into the targeting of 8D3 showed that it
could be detected in the brain one hour after injection [10].
However, contrary to reports in articles that cite this original
study, whilst experimental capillary depletion data was pro-
vided for one of the anti-transferrin receptor antibodies, Ri7,
no data was presented for 8D3. Therefore, it is impossible to
conclude from this study whether the 8D3 antibody had
reached the brain parenchyma, or whether it was retained
in the capillaries. Despite this lack of evidence for brain
penetration a number of studies were performed with 8D3
coupled to a variety of therapeutic or biologically active
molecules, such as targeted pegylated immunoliposomes
[11,12], radiolabelled peptides [13], antisense oligos [14],
and an enzyme [15]. All of these studies have concluded that
8D3 is able to penetrate into the brain parenchyma, but they
often focus on a single time point and/or lack appropriate
controls. For example; studies targeting 8D3 fusions to an
antisense oligo [14], to beta-galactoside [15] and to an A-beta
peptide [13] compare the 8D3-conjugated cargo to the free
cargo. The difference in the pharmacokinetics between the
cargo when conjugated to an antibody and the free cargo
makes it difficult to conclude whether or not it is 8D3 that is
conferring brain exposure. An irrelevant antibody fused to
the cargo would have been a far more informative control.
More recent work investigating the fate of anti-mouse
transferrin receptor antibodies injected systemically showed
that the 8D3 antibody bound to the endothelial cells of the
brain vasculature but found little evidence to suggest that the
antibodies were able to make their way deeper into the brain
parenchyma [16]. However, with the use of confocal micros-
copy, they were able to see some co-localisation with collagen
IV, which is a commonly used marker for the basal lamina,
suggesting that the antibodies were able to cross from the
luminal to the abluminal side of the brain endothelial
cells, but were not released from the abluminal transferrin
receptor.
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To be useful as a targeting system an anti-transferrin receptor
antibody needs to be able to deliver its cargo to the brain
parenchyma over an extended time frame consistent with the
peripheral half-life of the antibody, and show a significant
improvement over an isotype control antibody fused to the
same cargo. In 2011, a paper from researchers at Genentech
led to resurgence in interest in the transferrin receptor as a
‘Trojan horse’ for drug delivery across the brain. Yu et al. [17]
proposed that using an antibody with decreased affinity for
the transferrin receptor would allow release of the antibody
on the abluminal side of the BBB. Their hypothesis stated that
using a therapeutic dose of the lower affinity antibody rather
than a trace dose would overcome any issues that arose as a
result of the decreased level of binding. A panel of anti-mouse
transferrin receptor antibodies with a range of different affin-
ities was generated against the mouse transferrin receptor and
it was demonstrated that although the highest affinity anti-
body showed higher accumulation in the brain compared
with a control IgG following a therapeutic dose, the majority
was located in the capillaries of the brain even after 24 hours
when the control antibody could no longer be detected.
Investigating the panel of lower affinity mutant antibodies
dosed i.v. at a therapeutic level showed that the level of
antibody detectable in the brain after 24 hours was inversely
correlated with the antibody affinity for the transferrin re-
ceptor. Immunohistochemical analysis of perfused brains
24 hours after injecting the lower affinity antibodies showed
parenchymal localisation and some co-localisation with a
neuronal marker.
Further work from the same group offered some evidence
for a potential mechanism for the lower levels of brain
exposure of the high affinity transferrin receptor antibody.
Bien-Ly et al. [18] published details of an increase in the
internalisation and subsequent lysosomal degradation of
transferrin receptor following incubation with a high affinity
anti-transferrin receptor antibody compared to a lower affin-
ity or control antibody. The authors proposed that this
increased degradation of transferrin receptor contributed to
the lower brain exposure of high affinity anti-transferrin
receptor antibody as the antibody was degraded along with
the receptor, and the recycling of transferrin receptor that
would usually occur to bind more antibody at the cell surface
could not take place.
A second group also published data on the importance of
avoiding lysosomal degradation when targeting the brain via
the transferrin receptor, although they proposed that avidity
rather than affinity was the important factor in determining
the fate of an anti-transferrin receptor antibody at the BBB.
Niewoehner et al. [19] hypothesised that monovalent rather
than divalent binding of an antibody would better mimic the
monovalent binding of the endogenous ligand and lead to
better penetration into the brain. A direct comparison ofmonovalent (mFab) vs divalent (dFab) forms of an anti-mouse
transferrin receptor antibody showed in vitro that although
dFab was internalised at a faster rate, significantly more of it
was associated with a lysosomal marker than mFab. They also
showed that there was a reduced amount of transferrin
receptor recycled to the cell surface in response to treatment
with dFab, whereas mFab had no effect on the normal trans-
ferrin receptor pathway. The two formats of the mouse anti-
body were also used in vivo conjugated to an anti-amyloid
plaque antibody (mAb31) to look for target engagement on
the brain side of the BBB. mFab appeared to cross the endo-
thelial cells of the BBB and distribute throughout the paren-
chyma where the mAb31 was able to engage with and
decorate amyloid plaques, whereas dFab was restricted to
the vasculature and again associated with a lysosomal marker.
The authors discussed the possibility that divalent binding of
the antibody to the transferrin receptor may be causing
receptor dimerization and promoting trafficking to the lyso-
some. In addition to affinity and avidity, there is evidence
from another publication that pH-dependent receptor bind-
ing may be important in determining the sorting pathway of
an anti-transferrin receptor antibody [20]. Comparing vari-
ous commercially available antibodies it was demonstrated
that those that exhibited less efficient binding to transferrin
receptor in the lower pH environment of the late endosome
could be detected in the lower well of an in vitro transcytosis
experiment whereas pH-independent binders remained
trapped within cells.
Our own data has indicated that both 8D3 and OX26 are
able to efficiently bind to brain endothelial cells, but do not
penetrate further into the brain. Engineering either to reduce
their affinity for transferrin receptor results in a significant
increase in accumulation within the brain parenchyma (un-
published) and supports the reduced affinity hypothesis.
In reality it is likely that all of the parameters described
above, affinity, avidity and pH dependence, are likely to play
a part in the trafficking of anti-transferrin receptor antibodies
across the BBB. Only through the systematic evaluation of all
of these parameters will it become clear which, if any, is the
most important.
Path to the clinic
Alongside the positive aspects of targeting the transferrin
receptor for brain delivery of therapeutics, a note of caution
must also be raised. Transferrin receptor is expressed on cells
other than those of the brain endothelium and a study that
investigated the safety aspects of dosing with anti-transferrin
receptor antibodies found that a single dose of a high affinity
anti-transferrin receptor antibody caused acute clinical signs
and reticulocyte depletion in mice, even at low doses [21].
Reducing the affinity of the antibody attenuated the reticu-
locyte destruction in a dose-dependent manner. However, it
appeared to be effector function that was responsible for thewww.drugdiscoverytoday.com 51
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by introducing mutations into the Fc domain of the mono-
specific antibody eliminated the clinical signs although some
reticulocyte depletion was still observed.
Perhaps the most challenging aspect of moving anti-trans-
ferrin receptor antibodies to the clinic is the lack of species
cross reactivity observed in the available antibodies. Trans-
ferrin receptor is not highly conserved between species at the
level of the amino acid sequence and obtaining an antibody
that can be used for both pre-clinical studies and clinical
products may prove to be very difficult, especially as the
affinity towards each species of transferrin receptor is likely
to need to be maintained. The solution is to isolate an
antibody for use in each species under investigation, or
perhaps one for use in rodents, and one for primates, some-
thing that will add significantly to development costs.
Conclusions
For now, anti-transferrin receptor antibodies may not be the
answer to the biologics brain targeting question. However the
research performed with the available antibodies has provid-
ed invaluable insight into the mechanisms of action of
receptors at the BBB and has also helped to highlight protein
engineering issues that must be addressed in order for a
successful BBB shuttle to be developed.
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